Details of Disease

General Information of Disease (ID: DISGCAMX)

Disease Name	Neutropenia
Synonyms	neutropenic disorder; neutropenia
Disease Class	4B00: Neutropenia
Definition	A decrease in the number of neutrophils found in the blood.
Disease Hierarchy	DISJS4LS: Agranulocytosis DISGCAMX: Neutropenia
ICD Code	ICD-11 ICD-11: 4B00.0 ICD-9 ICD-9: 288 Expand ICD-11 '4B00.0 Expand ICD-9 288
Disease Identifiers	MONDO ID MONDO_0001475 UMLS CUI C0853697 MedGen ID 163121 HPO ID HP:0001875 SNOMED CT ID 165517008

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Efbemalenograstim	DMDNJ18	Approved	NA	[1]
Eflapegrastim	DMACVEI	Approved	NA	[2]
Tbo-Filgrastim	DML6OE7	Approved	NA	[3]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 8 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Neugranin	DMLRKJX	Preregistration	NA	[4]
DA-3031	DM6S4R2	Phase 3	Small molecular drug	[5]
LA-EP2006	DMI3YLK	Phase 3	NA	[6]
MK-4214	DMA25NO	Phase 3	NA	[7]
MAXY-G34	DMWLIPJ	Phase 2	NA	[8]
Romyelocel-L	DMTFO7B	Phase 2	Cell therapy	[9]
SBC-014	DMG1VXR	Phase 2	NA	[10]
MK-6302	DMZUA5C	Phase 1	NA	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

This Disease is Treated as An Indication in 9 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BBT-007	DMT0X6Q	Investigative	NA	[11]
BBT-015	DMYWDIX	Investigative	NA	[12]
BBT-018	DM7XT4I	Investigative	NA	[12]
GC-003	DMFRP7G	Investigative	NA	[12]
IRX-03	DM96390	Investigative	NA	[12]
MGMTP140K gene-modified hematopoietic progenitor cells	DM40V5L	Investigative	NA	[12]
SRG	DMU4AT6	Investigative	Small molecular drug	[12]
ST-7	DMWN2M3	Investigative	NA	[12]
ZP-G-CSF	DM9XFYZ	Investigative	NA	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ELANE	TTPLTSQ	Definitive	Autosomal dominant	[14]
------------------------------------------------------------------------------------

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC35A2	DT0567K	Strong	Genetic Variation	[15]
------------------------------------------------------------------------------------

This Disease Is Related to 1 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ELANE	OTCOHLXR	Definitive	Autosomal dominant	[14]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761134
2	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761148.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6968).
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017176)
5	ClinicalTrials.gov (NCT01674855) Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia. U.S. National Institutes of Health.
6	ClinicalTrials.gov (NCT01516736) Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim. U.S. National Institutes of Health.
7	Clinical pipeline report, company report or official report of Merck.
8	ClinicalTrials.gov (NCT00501332) Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy. U.S. National Institutes of Health.
9	ClinicalTrials.gov (NCT02282215) Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia. U.S. National Institutes of Health.
10	ClinicalTrials.gov (NCT00497809) Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia. U.S. National Institutes of Health.
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
12	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
13	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
14	Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
15	SLC35A2-CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals.Hum Mutat. 2019 Jul;40(7):908-925. doi: 10.1002/humu.23731. Epub 2019 Apr 24.